Esomeprazole News and Research

RSS

Esomeprazole is a drug that blocks acid from being made in the stomach. It is used to treat acid reflux disease and to prevent certain types of gastrointestinal ulcers. Esomeprazole magnesium is being studied in the prevention of esophageal cancer and in the treatment of other conditions, including side effects of chemotherapy. It is a type of anti-ulcer agent. Also called esomeprazole and Nexium.

Prescription heartburn medications do not ease asthma symptoms

The predominance of heartburn among asthma sufferers led many specialists to suspect that acid reflux could be a trigger for the coughing, wheezing and breathlessness of asthma.

9 Apr 2009

National study results change common method of treating asthma

A nationwide study of adults with asthma reveals no benefit for treatment for silent acid reflux, which long has been thought to be the culprit for some severe asthma symptoms such as coughing, wheezing and breathlessness.

8 Apr 2009

Is esomeprazole the best choice for reflux esophagitis patients?

In patients with gastroesophageal reflux disease (GERD), esomeprazole, has demonstrated pharmacological and clinical benefits beyond those seen with the other proton pump inhibitors (PPIs).

2 Apr 2009

Is esomeprazole the best choice for reflux esophagitis patients?

In patients with gastroesophageal reflux disease (GERD), esomeprazole, has demonstrated pharmacological and clinical benefits beyond those seen with the other proton pump inhibitors (PPIs).

3 Mar 2009

AstraZeneca submits sNDA for NEXIUM (esomeprazole magnesium)

AstraZeneca has announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for NEXIUM(R) (esomeprazole magnesium) to seek approval for the short-term (up to 6 weeks) treatment of gastroesophageal reflux disease (GERD) in pediatric patients ages 0 to 1 year old.

21 Dec 2008

FDA approves Nexium for gastroesophageal reflux disease in children

The U.S. Food and Drug Administration approved Nexium (esomeprazole magnesium) for short-term use in children ages 1-11 years for the treatment of gastroesophageal reflux disease (GERD).

28 Feb 2008

Ranbaxy receives tentative approval for Esomeprazole Magnesium delayed-release capsules

Ranbaxy Laboratories Limited has announced that it has received tentative approval from the U.S. Food and Drug Administration for Esomeprazole Magnesium Delayed-Release Capsules, 20 mg (base) and 40 mg (base).

8 Feb 2008

FDA concludes no increased risk of cardiac events for patients treated with omeprazole and Nexium

The US Food and Drug Administration (FDA) has issued its final assessment of two small, open, long-term, clinical studies in patients with gastro-esophageal reflux disease (GERD), comparing anti-reflux surgery with either omeprazole (SOPRAN study) or NEXIUM (LOTUS study) treatment.

10 Dec 2007

FDA taking no chances when it comes to drug safety

These days the U.S. Food and Drug Administration (FDA) is taking no chances when it comes to the safety of new drugs.

13 Aug 2007

Treatment reduces gastric ulcers in at-risk patients using long-term NSAIDS

Esomeprazole magnesium can reduce the incidence of gastric (stomach) ulcers in patients at risk of developing gastric ulcers and who regularly take either non-selective nonsteroidal anti-inflammatory drugs (NSAIDs) or COX-2-selective NSAIDs

30 Mar 2006

AstraZeneca starts patent infringement litigation against IVAX

AstraZeneca announced today that it has filed a lawsuit in the United States District Court for the District of New Jersey against IVAX Corporation, IVAX Pharmaceuticals and Zenith Laboratories

8 Mar 2006

Treating nighttime heartburn improves sleep and boosts quality of life

The first major multi-center, randomized, double-blind, placebo-controlled trial addressing therapy for gastroesophageal reflux disease (GERD) related sleep disorders is published in the September issue of The American Journal of Gastroenterology.

1 Sep 2005

Heart patients with gastrointestinal complications should use low doses of aspirin combined with drugs that treat stomach ulcers

Physicians are challenged in treating heart patients who may be at high-risk for gastrointestinal bleeding from aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs). Factors that place patients at high-risk include a history of ulcers or gastrointestinal complications such as bleeding, increased age and congestive heart failure.

20 Jan 2005

Canadian Rheumatology Association issues statement on Vioxx alternatives

The Canadian Rheumatology Association (CRA) has issued a statement to its 350 members and other interested parties, recommending alternative treatment considerations in the wake of the worldwide recall of Merck's rofecoxib, (Vioxx(R)) last week.

7 Oct 2004